N/A
Completed N=24
Special Investigation of Kaletra in Pregnant Women
Source: ClinicalTrials.gov NCT01076985 ↗Enrolled (actual)
24
Serious AEs
13.3%
Results posted
Jan 2012
Primary outcomePrimary: Number of Patients With Adverse Drug Reactions (ADRs) — 2; 5; 1; 0 participants
Summary
This non-interventional, post-marketing observational study was conducted to obtain safety data from the use of lopinavir/ritonavir (Kaletra), in clinical practice, in pregnant women and their children in Japan.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With Adverse Drug Reactions (ADRs) |
2; 5; 1; 0; 1; 0 | — |
Eligibility Criteria
Inclusion Criteria
- All pregnant women who have received Kaletra for the treatment of HIV infection were eligible for this study
Exclusion Criteria
- Contraindications according to the Package Insert:
- Patients with a history of hypersensitivity to any ingredient of Kaletra
- Patients who are receiving pimozide, cisapride, ergotamine tartrate, dihydroergotamine mesylate, ergometrine maleate, methylergometrine maleate, midazolam, triazolam, vardenafil hydrochloride hydrate, boriconazol
Data sourced from ClinicalTrials.gov (NCT01076985). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.